Detection of Non-Small Lung Cell Carcinoma-Associated Genetic Alterations Using a NanoString Gene Expression Platform Approach

Johan Staaf; Mats Jönsson; Anna F Karlsson

doi:10.1007/978-1-0716-1278-1_8

Detection of Non-Small Lung Cell Carcinoma-Associated Genetic Alterations Using a NanoString Gene Expression Platform Approach

Methods Mol Biol. 2021:2279:91-107. doi: 10.1007/978-1-0716-1278-1_8.

Authors

Johan Staaf¹, Mats Jönsson¹, Anna F Karlsson²

Affiliations

¹ Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
² Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. Anna_F.Karlsson@med.lu.se.

PMID: 33683688
DOI: 10.1007/978-1-0716-1278-1_8

Abstract

In non-small cell lung cancer (NSCLC), mutation detection and fusion gene status are treatment predictive and, hence, key factors in clinical management. Lately, alternate splicing variants of MET have gained focus as NSCLC tumors harboring a MET exon 14 skipping event have proven sensitive toward targeted therapy. Reliable methods for detection of genetic alterations in NSCLC have proven to be of increased importance. This chapter provides with hands-on experience of the NanoString gene expression platform for detection of genetic alterations in NSCLC.

Keywords: Fusion gene; Gene expression; NanoString; Non-small cell lung carcinoma.

MeSH terms

Alternative Splicing*
Carcinoma, Non-Small-Cell Lung* / diagnosis
Carcinoma, Non-Small-Cell Lung* / enzymology
Carcinoma, Non-Small-Cell Lung* / genetics
Exons*
Gene Expression Regulation, Neoplastic*
Humans
Lung Neoplasms* / diagnosis
Lung Neoplasms* / enzymology
Lung Neoplasms* / genetics
Proto-Oncogene Proteins c-met* / biosynthesis
Proto-Oncogene Proteins c-met* / genetics

Substances

MET protein, human
Proto-Oncogene Proteins c-met